End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.65 CNY | -0.66% |
|
-7.06% | -32.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.12% | 3.79B | C | ||
-55.19% | 10.1B | B- | ||
-47.06% | 8.81B | B | ||
-26.42% | 6.65B | B | ||
-3.72% | 6.45B | C+ | ||
+97.00% | 5.35B | C | ||
-2.48% | 4.63B | D- | ||
+8.08% | 4.6B | B | ||
+6.99% | 3.13B | B | ||
-23.13% | 2.56B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.